K1-70 — A Thyrotropin Receptor Antagonist with Therapeutic Potential in Graves' Disease, Thyroid Eye Disease, and Differentiated Thyroid Cancer

Abstract

BackgroundThe thyrotropin (TSH) receptor (TSHR) is a major thyroid autoantigen and plays a key role in the regulation of thyroid function (1). Graves' disease typically manifests with hyperthyroidism caused by TSHR autoantibodies (TRAbs) with agonist (stimulating) activity. Rarely, patients may develop hypothyroidism due to a predominance of antagonist (blocking) TRAbs (1).